Mosaic ImmunoEngineering is a nanotechnology-based immunotherapy company developing therapeutics and vaccines to positively impact the lives of patients and their families.

Free
Message: We project Crossflo/Iameter profitability by fiscal year 2009 Q4 (May 2009)

Figures won't be exactly known until the release of the next 10-Q.......As per an IR question I had raised....

The SEC requires that the Crossflo audited financials for the most recent two fiscal years (using the PTSC year end of May 31 to be released, which they were. The next required reporting period will be the first quarter of their inclusion in the Patriot 10Q, which would be for the quarter ending November 30. The SEC does not require the quarter in between (prior to the acquisition closing) to be reported as Crossflo was still a private company at that time. You will see our numbers in the next PTSC 10Q and there will be accompanying footnotes to help you process the information.

Share
New Message
Please login to post a reply